Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Koninklijke Philips N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

POLAREAN'S FDA CLEARED COIL ACHIEVES IMPORTANT MILESTONE, EXPANDING CLINICAL REACH POLAREAN'S FDA CLEARED COIL ACHIEVES IMPORTANT MILESTONE, EXPANDING CLINICAL REACH

XENOVIEW 3T COIL PASSES PHILIPS COMPATIBILITY TESTING

DECEMBER 1, 2025 COMMERCIAL AVAILABILITY EXPANDED ACROSS EUROPE AND THE UNITED STATES REAL-TIME AI-ENABLED 3D DEVICE VISUALIZATION POWERED BY LIGHT INSTEAD OF X-RAY, IMPROVING NAVIGATION IN COMPLEX ENDOVASCULAR PROCEDURES LUMIGUIDE SEAMLESSLY INTEGRATES WITH AZURION, PHILIPS' PROVEN, WORLD-LEADING IMAGE-GUIDED THERAPY PLATFORM DESIGNED TO DRIVE PROCEDURAL INNOVATION ACROSS CLINICAL DOMAINS AMSTERDAM, THE NETHERLANDS AND CHICAGO, USA  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA, A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY ANNOUNCED THE EXPANDED COMMERCIAL AVAILABILITY OF LUMIGUIDE 3D DEVICE GUIDANCE, THE WORLD'S FIRST REAL-TIME AI-ENABLED LIGHT-BASED 3D NAVIGATION SOLUTION FOR IMAGE-GUIDED THERAPY, ACROSS EUROPE AND THE UNITED STATES. LUMIGUIDE REPRESENTS A BREAKTHROUGH IN RADIATION-FREE* NAVIGATION, ALLOWING PHYSICIANS TO VISUALIZE AND GUIDE DEVICES INSIDE THE BODY USING LIGHT INSTEAD OF CONTINUOUS X-RAY.

PHILIPS EXPANDS COMMERCIAL AVAILABILITY OF WORLD'S FIRST REAL-TIME AI-ENABLED LIGHT-BASED 3D NAVIGATION SOLUTION FOR IMAGE-GUIDED THERAPY

NOVEMBER 30, 2025 PHILIPS PIONEERED DETECTOR-BASED SPECTRAL CT, WHICH HAS BEEN WIDELY ADOPTED IN CLINICAL ROUTINE EXAMS ACROSS ANATOMIES, SUPPORTED BY OVER 800 PEER-REVIEWED PUBLICATIONS [1] CE-MARKED, 510K PENDING VERIDA CT [2] INTEGRATES AI ACROSS THE IMAGING CHAIN, PROVIDING SUPERB IMAGE QUALITY WHILE ACCELERATING WORKFLOW AND REDUCING DOSE [3, 4] AMSTERDAM, THE NETHERLANDS AND CHICAGO, USA  AT RSNA 2025, ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY ANNOUNCED THE LAUNCH OF VERIDA, THE WORLD'S FIRST DETECTOR-BASED SPECTRAL CT FULLY POWERED BY AI. THIS MARKS A TRANSFORMATIVE MILESTONE IN CT, WITH AI OPTIMIZING THE ENTIRE IMAGING CHAIN  LOWERING SYSTEM NOISE, ELEVATING IMAGE QUALITY, AND ACCELERATING CLINICAL WORKFLOW.

PHILIPS LAUNCHES VERIDA, WORLD'S FIRST DETECTOR-BASED SPECTRAL CT POWERED BY BREAKTHROUGH AI, TO ADVANCE DIAGNOSTIC PRECISION

NOVEMBER 30, 2025 MAJOR TECHNOLOGY BREAKTHROUGH COMBINES ADVANCED AI FOR CLINICAL INSIGHTS AND ACCELERATED WORKFLOW IN NEW PREMIUM 3.0T MRI PLATFORM [1] AMSTERDAM, THE NETHERLANDS, AND CHICAGO, USA  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY UNVEILED BLUESEAL HORIZON [1], AN ENTIRELY NEW 3.0T MRI INNOVATION PLATFORM THAT INCLUDES THE INDUSTRY'S FIRST HELIUM-FREE 3.0T MAGNET AT RSNA 2025. A PIVOTAL ADVANCE IN MRI INNOVATION, HELIUM-FREE [2] 3.0T IS A MAJOR SCIENTIFIC ACHIEVEMENT SET TO HAVE SIGNIFICANT IMPACT FOR HEALTH PROVIDERS AND PATIENTS.

PHILIPS UNVEILS BLUESEAL HORIZON, INDUSTRY'S FIRST HELIUM-FREE 3.0T MRI PLATFORM

NOVEMBER 24, 2025 NEW VIEWER OFFERS FULL RADIOLOGY CAPABILITIES, INTERFACES WITH AI AND INTERACTIVE REPORTING MODULE TO STREAMLINE WORKFLOWS AMSTERDAM, THE NETHERLANDS  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY ANNOUNCED THE LAUNCH OF PHILIPS IMAGE MANAGEMENT 15, THE NEXT GENERATION OF PHILIPS VUE PACS, INCLUDING A ZERO-FOOTPRINT, WEB DIAGNOSTIC VIEWER [1] THAT TRANSFORMS HOW RADIOLOGISTS ACCESS AND INTERPRET MEDICAL IMAGES. DESIGNED WITH A BRAND-NEW USER INTERFACE, THE VIEWER DELIVERS THE FULL CLINICAL POWER OF A DESKTOP WORKSTATION THROUGH A STANDARD WEB BROWSER.

PHILIPS LAUNCHES NEXT-GENERATION WEB-BASED DIAGNOSTIC VIEWER FOR FAST, SECURE IMAGING DATA ACCESS ANYWHERE

NOVEMBER 19, 2025 AMSTERDAM, THE NETHERLANDS  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY ANNOUNCED AN EXTENDED PARTNERSHIP WITH CORTECHS.AI, A PIONEER IN QUANTITATIVE NEUROIMAGING SOLUTIONS. TOGETHER, THE COMPANIES WILL INTEGRATE CORTECHS.AI'S ADVANCED AI-ENABLED NEUROIMAGING ANALYTICS DIRECTLY INTO PHILIPS' MR SYSTEMS [1], EMPOWERING CLINICIANS WITH FASTER, MORE OBJECTIVE, AND REPRODUCIBLE INSIGHTS INTO BRAIN HEALTH. THE COLLABORATION STRENGTHENS PHILIPS' LEADERSHIP IN PRECISION NEURO DIAGNOSTICS, COMBINING PHILIPS' NEXT-GENERATION MR TECHNOLOGIES WITH CORTECHS.AI'S AI-DRIVEN QUANTITATIVE NEURO IMAGING POST PROCESSING SOFTWARE [1] TO TRANSFORM HOW NEUROLOGICAL DISEASES ARE DETECTED, MONITORED, AND MANAGED. COMBINING COMPLEMENTARY EXPERTISE FOR SMARTER BRAIN IMAGING UP TO 25% [2] OF ALL MR PROCEDURES ARE BRAIN SCANS, AND RADIOLOGY DEPARTMENTS FACE GROWING DEMAND AMID INCREASING STAFF SHORTAGES. AT THE SAME TIME, THE NUMBER OF PATIENTS WITH NEUROLOGICAL CONDITIONS SUCH AS ALZHEIMER'S DISEASE, MULTIPLE SCLEROSIS (MS), AND BRAIN TUMORS CONTINUE TO RISE GLOBALLY. CURRENT MR INTERPRETATION OF NEURODEGENERATIVE DISEASES OR NEURO ONCOLOGY CASES DEPENDS HEAVILY ON VISUAL ASSESSMENT, INTRODUCING VARIABILITY AND REQUIRING SIGNIFICANT EXPERTISE AND TIME IN AN ALREADY OVERLOADED SYSTEM. THROUGH THIS EXTENDED PARTNERSHIP, PHILIPS AND CORTECHS.AI AIM TO DELIVER MORE STANDARDIZED AND DATA-DRIVEN IMAGING. BY INTEGRATING QUANTITATIVE ANALYSIS TOOLS SUCH AS BRAIN VOLUMETRICS, LESION QUANTIFICATION, AND TUMOR TRACKING DIRECTLY INTO THE PHILIPS MR IMAGING WORKFLOW [1], CLINICIANS GAIN OBJECTIVE, NUMERICAL DATA ALONGSIDE IMAGES  ENABLING FASTER, MORE CONSISTENT, AND CONFIDENT DIAGNOSES. EMPOWERING CLINICIANS WITH PRECISION AND SPEED THE INTEGRATION OF CORTECHS.AI'S NEUROQUANT SOLUTIONS FOR ALZHEIMER'S, MS AND BRAIN TUMORS WITHIN PHILIPS' SMART READING ENVIRONMENT  A CLOUD-BASED AI PLATFORM THAT COMBINES IMAGING, READING, AND REPORTING DIRECTLY ON T

PHILIPS AND CORTECHS.AI EXTEND PARTNERSHIP TO ADVANCE QUANTITATIVE NEUROIMAGING AND STRENGTHEN PHILIPS' LEADERSHIP IN PRECISION DIAGNOSTICS IN NEUROLOGY

NOVEMBER 17, 2025 INNOVATION USES AI TO TRACK AND VISUALIZE TINY REPAIR DEVICES* THROUGH THE BEATING HEART, HELPING CLINICIANS NAVIGATE IN 3D WITH ENHANCED CLARITY AND CONFIDENCE** AMSTERDAM, THE NETHERLANDS  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY INTRODUCED DEVICEGUIDE, AN AI-POWERED DEVICE TRACKING* SOLUTION THAT ASSISTS PHYSICIANS DURING ONE OF INTERVENTIONAL CARDIOLOGY'S MOST TECHNICALLY DEMANDING PROCEDURES: REPAIRING LEAKING HEART VALVES THROUGH A MINIMALLY INVASIVE APPROACH. BUILT ON PHILIPS' ECHONAVIGATOR PLATFORM, THIS SOFTWARE BRINGS AI DIRECTLY INTO THE PROCEDURE ROOM, TRANSLATING COMPLEX IMAGING INTO INTUITIVE, REAL-TIME VISUAL GUIDANCE THAT HELPS CLINICIANS NAVIGATE THE BEATING HEART WITH GREATER CLARITY AND CONFIDENCE.

PHILIPS BRINGS AI INTO THE PROCEDURE ROOM TO ASSIST DOCTORS DURING HEART VALVE REPAIR

NOVEMBER 4, 2025 Q3 2025 GROUP HIGHLIGHTS COMPARABLE ORDER INTAKE GROWTH 8% GROUP SALES AMOUNTED TO EUR 4.3 BILLION, REFLECTING 3% INCREASE IN COMPARABLE SALES INCOME FROM OPERATIONS WAS EUR 330 MILLION ADJUSTED EBITA MARGIN INCREASED BY 50 BASIS POINTS TO 12.3% OF SALES OPERATING CASH FLOW OF EUR 327 MILLION, WITH A FREE CASH FLOW OF EUR 172 MILLION PHILIPS REITERATES FULL-YEAR 2025 OUTLOOK, WITH MARGIN NOW EXPECTED AT THE UPPER END OF THE RANGE ROY JAKOBS, CEO OF ROYAL PHILIPS: IN THIS QUARTER WE MAINTAINED OUR MOMENTUM, WITH AI-POWERED INNOVATIONS AND LONG-TERM PARTNERSHIPS MAKING A REAL DIFFERENCE FOR PATIENTS AND CONSUMERS. WE DROVE STRONG ORDER INTAKE AND ACCELERATED SALES GROWTH, WITH SUSTAINED STRENGTH IN NORTH AMERICA.

PHILIPS CONTINUES MOMENTUM; DELIVERS STRONG ORDER INTAKE, STEP-UP IN SALES GROWTH AND MARGIN EXPANSION

CAMBRIDGE, MASS.--(BUSINESS WIRE)--ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY ANNOUNCED ITS SUPPORT OF THE FOREVER PROMISE PROJECT, AN INITIATIVE OF THE MONUMENTS MEN AND WOMEN FOUNDATION THAT CONNECTS AMERICAN FAMILIES OF FALLEN WORLD WAR II SERVICE MEMBERS WITH THE DUTCH CITIZENS WHO HAVE LOVINGLY ADOPTED THEIR GRAVES AT THE NETHERLANDS AMERICAN CEMETERY IN MARGRATEN. PHILIPS WILL HELP ADVANCE THE FOUNDATION'S MISSION TO CONNECT ALL 10,000 AMERICAN FAMIL.

PHILIPS JOINS THE FOREVER PROMISE PROJECT TO HONOR AMERICAN VETERANS

OCTOBER 30, 2025 10-YEAR COLLABORATION AIMS TO CONNECT SCALABLE MONITORING TECHNOLOGY THAT STREAMLINES WORKFLOWS, SUPPORTING PATIENT SAFETY AND THE PATIENT AND CLINICIAN EXPERIENCE AMSTERDAM, THE NETHERLANDS AND NEWPORT BEACH, CALIF., USA  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, AND HOAG, ORANGE COUNTY, CALIFORNIA'S HIGHEST-RANKED HOSPITAL, TODAY ANNOUNCED A LANDMARK 10-YEAR STRATEGIC COLLABORATION.

HOAG SELECTS PHILIPS TO ENHANCE AND UNIFY PATIENT MONITORING, ELEVATING CARE ACROSS ORANGE COUNTY, USA

OCTOBER 29, 2025 3-YEAR DATA FROM THE LARGEST GLOBAL TRIAL TO DATE USING CLASS I, LEVEL A IFR IN HEART ATTACK PATIENTS SHOWS TREATING ADDITIONAL STENOSES IN THE SAME PROCEDURE SHOWED NO SIGNIFICANT DIFFERENCE IN MAJOR OUTCOMES COMPARED WITH WAITING FOR FOLLOW-UP ADDITIONAL RESULTS FROM THE ILIAS ANOCA STUDY HIGHLIGHT THE SUSTAINED BENEFITS OF PHYSIOLOGY-GUIDED ASSESSMENT AND TAILORED MEDICAL THERAPY FOR PATIENTS WITH ANGINA AND NO OBSTRUCTIVE CORONARY ARTERIES AMSTERDAM, THE NETHERLANDS  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY ANNOUNCED LATE-BREAKING RESULTS FROM THE IMODERN TRIAL (INSTANTANEOUS WAVE-FREE RATIO GUIDED MULTIVESSEL REVASCULARISATION DURING PCI FOR ACUTE MYOCARDIAL INFARCTION) AT THE TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT) 2025 CONFERENCE, THE WORLD'S LEADING MEETING FOR INTERVENTIONAL CARDIOLOGY. THE STUDY COMPARED IMMEDIATE VERSUS DELAYED TREATMENT OF ADDITIONAL NARROWED ARTERIES IN HEART ATTACK PATIENTS TO DETERMINE WHETHER TREATING ALL BLOCKAGES IN ONE PROCEDURE IS AS SAFE AND EFFECTIVE AS WAITING FOR A FOLLOW-UP PROCEDURE.

LATE-BREAKING IMODERN FINDINGS PRESENTED AT TCT 2025 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE HIGHLIGHT NEW EVIDENCE TO GUIDE TREATMENT CHOICES FOR HEART ATTACK PATIENTS

OCTOBER 27, 2025 NEW INTEGRATION OF PHILIPS ADVANCED VISUALIZATION WORKSPACE* WITH THE AZURION IMAGE-GUIDED THERAPY PLATFORM AUTOMATICALLY SYNCHRONIZES CT IMAGES WITH C-ARM MOVEMENT, SUPPORTING WORKFLOW EFFICIENCY AND ADDITIONAL ANATOMICAL INSIGHTS IN PCI PROCEDURES1 SAN FRANCISCO, USA AND AMSTERDAM, THE NETHERLANDS  AT THE ANNUAL TRANSCATHETER CARDIOVASCULAR THERAPEUTICS (TCT 2025) MEETING, ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY INTRODUCED AN INDUSTRY-FIRST INNOVATION THAT INTEGRATES PRE-OPERATIVE CT DATA DIRECTLY INTO THE CATH LAB WORKFLOW. THIS NEW CAPABILITY, AVAILABLE THROUGH THE INTEGRATION OF PHILIPS' ADVANCED VISUALIZATION WORKSPACE (AVW) WITH THE AZURION IMAGE-GUIDED THERAPY SYSTEM, MARKS A FIRST STEP TOWARDS CT-GUIDED PERCUTANEOUS CORONARY INTERVENTION (PCI), A MINIMALLY INVASIVE PROCEDURE TO OPEN NARROWED CORONARY ARTERIES AND RESTORE BLOOD FLOW TO THE HEART.

PHILIPS INTRODUCES INDUSTRY-FIRST CATH LAB INTEGRATION THAT AUTOMATICALLY SYNCHRONIZES PRE-OPERATIVE CT WITH C-ARM MOVEMENT, PAVING THE WAY FOR CT-GUIDED PCI

OCTOBER 8, 2025 GLOBAL ADOPTION MILESTONE UNDERSCORES INNOVATION IN MOBILE C-ARM SURGICAL AND INTERVENTIONAL IMAGING, WITH MORE THAN 15 MILLION PATIENTS TREATED IN 170+ COUNTRIES EVERY YEAR AMSTERDAM, THE NETHERLANDS  ROYAL PHILIPS (NYSE: PHG, AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, TODAY ANNOUNCED THE 5,000TH INSTALLATION OF ITS PHILIPS ZENITION MOBILE SURGERY IMAGING SYSTEM AT KOLN REGIONAL HOSPITAL IN THE CZECH REPUBLIC. SINCE ITS LAUNCH IN 2019, ZENITION HAS BECOME A TRUSTED SOLUTION IN HOSPITALS ACROSS MORE THAN 170 COUNTRIES, ENABLING SURGEONS AND INTERVENTIONAL TEAMS TO PERFORM IMAGE-GUIDED PROCEDURES MORE EFFICIENTLY, SUPPORTING IMPROVED TREATMENT OUTCOMES.

PHILIPS ANNOUNCES 5,000TH ZENITION MOBILE C-ARM SYSTEM INSTALLATION, ADVANCING ACCESS TO HIGH-QUALITY, EFFICIENT SURGICAL AND INTERVENTIONAL CARE WORLDWIDE

DUBAI,UAE, OCT. 7, 2025 /PRNEWSWIRE/ -- ROYAL PHILIPS (NYSE: PHG) (AEX: PHIA), A GLOBAL LEADER IN HEALTH TECHNOLOGY, HAS RELEASED THE SECOND EDITION OF THE PHILIPS HEALTH TRENDS RESEARCH UAE. CONDUCTED BY MARKET RESEARCH FIRM CENSUSWIDE, THE STUDY EXPLORES PEOPLE'S PERCEPTIONS ACROSS KEY ASPECTS OF HEALTH.

Koninklijke Philips N.V.

PHG

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Koninklijke Philips N.V.

PHG.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PHG